Sarah Weiss, MD

• Adebowale Adeniran
• Aldo Peixoto
• Ana Luisa Perdigoto
• Andrew Esposito
• Anjela Galan
• Daniel Boffa
• Daniel Jacobs
• David Schoenfeld
• Dijana Djureinovic
• Frank Detterbeck
• Gail Anderson
• Harriet Kluger
• John Sinard
• Jonathan Leventhal
• Kelly Olino
• Kevan Herold
• Koonam Park
• Lucia Jilaveanu
• Marcus Bosenberg
• Mario Sznol
• Michael Hurwitz
• Ninani Kombo
• Robert Camp
• Sajid A Khan
• Sarah Goldberg
• Scott Gettinger
• Shawn Cowper
• Stephan Ariyan
• Thuy Tran
• Veronica Chiang
• William Damsky
• Yuval Kluger

Immunotherapy; Melanoma

Cancer

• A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.
• A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1Weiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Muñoz-Couselo E, Rodríguez-Abreu D, Boni V, Schuchter L, Cao M, Fernandez A, Wei W, Ganti A, Hauke R, Berrocal A, Iannotti N, Hsu F, Kluger H. A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1. Clinical Cancer Research 2023, 30: 74-81. PMID: 37535056, PMCID: PMC10767304, DOI: 10.1158/1078-0432.ccr-23-0475.
• Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.
• Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastasesRusheen J, Clune J, Ariyan S, Baumann R, Kluger H, Olino K, Weiss S. Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases. Frontiers In Oncology 2023, 13: 1217816. PMID: 37476373, PMCID: PMC10354444, DOI: 10.3389/fonc.2023.1217816.
• The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative diseasePapageorge M, Maina R, King A, Lee V, Baumann R, Pucar D, Ariyan S, Khan S, Weiss S, Clune J, Olino K. The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease. Frontiers In Oncology 2023, 13: 1143354. PMID: 37223678, PMCID: PMC10200883, DOI: 10.3389/fonc.2023.1143354.
• Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments anti-tumor activity in melanomaTran T, Caulfield J, Zhang L, Schoenfeld D, Djureinovic D, Chiang V, Oria V, Weiss S, Olino K, Jilaveanu L, Kluger H. Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments anti-tumor activity in melanoma. JCI Insight 2023, 8: e157347. PMID: 36821392, PMCID: PMC10132152, DOI: 10.1172/jci.insight.157347.
• Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDjureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Cancer Research 2023, 83: 3287-3287. DOI: 10.1158/1538-7445.am2023-3287.
• 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapyWeiss S, Sznol M, Shaheen M, Berciano-Guerrero M, Felip E, Rodríguez-Abreu D, Arance A, Boni V, Linette G, Schuchter L, Gonzalez-Cao M, Iannotti N, Ganti A, Hauke R, Berrocal A, Filbert E, Kluger H. 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Journal For ImmunoTherapy Of Cancer 2021, 9: a422-a422. DOI: 10.1136/jitc-2021-sitc2021.389.
• ASO Visual Abstract: Merkel Cell Carcinoma—Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and NationallyEsposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. ASO Visual Abstract: Merkel Cell Carcinoma—Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals Of Surgical Oncology 2021, 28: 736-737. DOI: 10.1245/s10434-021-10784-7.
• Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysisSandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.
• Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastasesWeiss SA, Zito C, Tran T, Heishima K, Neumeister V, McGuire J, Adeniran A, Kluger H, Jilaveanu LB. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal Of Neuro-Oncology 2020, 152: 15-25. PMID: 32974852, PMCID: PMC7910371, DOI: 10.1007/s11060-020-03619-0.
• 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMAOria V, Zhang H, Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, Jilaveanu L. 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA. Neuro-Oncology Advances 2020, 2: ii3-ii3. PMCID: PMC7401364, DOI: 10.1093/noajnl/vdaa073.009.
• Systemic Therapy for Brain Metastases: MelanomaWeiss S, Kluger H. Systemic Therapy for Brain Metastases: Melanoma. 2020, 235-244. DOI: 10.1007/978-3-030-42958-4_16.
• Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case seriesLigtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.
• Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanomaKlemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For ImmunoTherapy Of Cancer 2020, 8: e000341. PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.
• Prognostic and Predictive Biomarkers in Oligometastatic Disease.Barnum KJ, Weiss SA. Prognostic and Predictive Biomarkers in Oligometastatic Disease. The Cancer Journal 2020, 26: 100-107. PMID: 32205533, PMCID: PMC9208067, DOI: 10.1097/ppo.0000000000000438.
• Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseAbu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal Of Clinical Oncology 2019, 38: 576-583. PMID: 31800340, PMCID: PMC7030892, DOI: 10.1200/jco.19.01674.
• PLEKHA5 regulates tumor growth in metastatic melanomaZhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, Jilaveanu LB. PLEKHA5 regulates tumor growth in metastatic melanoma. Cancer 2019, 126: 1016-1030. PMID: 31769872, PMCID: PMC7147081, DOI: 10.1002/cncr.32611.
• RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTSKluger H, Forsyth P, Khushalani N, Eroglu Z, Sznol M, Tran T, Jilaveanu L, Cohen J, Hegde U, Wei W, Mahajan A, Goldberg S, Chiang V, Weiss S. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS. Neuro-Oncology 2019, 21: vi220-vi220. PMCID: PMC6847787, DOI: 10.1093/neuonc/noz175.919.
• Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanomaGao CA, Weber UM, Peixoto AJ, Weiss SA. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 262. PMID: 31623673, PMCID: PMC6796437, DOI: 10.1186/s40425-019-0748-0.
• Immunotherapy of Melanoma: Facts and HopesWeiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clinical Cancer Research 2019, 25: 5191-5201. PMID: 30923036, PMCID: PMC6726509, DOI: 10.1158/1078-0432.ccr-18-1550.
• Dabrafenib and Trametinib for BRAF-Mutated Conjunctival MelanomaKim JM, Weiss S, Sinard JH, Pointdujour-Lim R. Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma. Ocular Oncology And Pathology 2019, 6: 35-38. PMID: 32002403, PMCID: PMC6984155, DOI: 10.1159/000497473.
• Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanomaKlemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.
• Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)Kluger H, Weiss S, Olszanski A, Schuchter L, Linette G, Garland L, Iannotti N, Johnson M, Avsar E, Srivastava M, Trifan O, Edelman M. Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Research 2019, 79: ct089-ct089. DOI: 10.1158/1538-7445.am2019-ct089.
• Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)Kluger H, Weiss S, Olszanski A, Schuchter L, Linette G, Garland L, Iannotti N, Johnson M, Avsar E, Srivastava M, Trifan O, Edelman M. Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). 2019, ct089-ct089. DOI: 10.1158/1538-7445.sabcs18-ct089.
• Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case SeriesKim J, Materin MA, Sznol M, Kluger H, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology 2019, 126: 1058-1062. PMID: 30735682, PMCID: PMC6933747, DOI: 10.1016/j.ophtha.2019.01.031.
• Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialKluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal Of Clinical Oncology 2018, 37: 52-60. PMID: 30407895, PMCID: PMC6354772, DOI: 10.1200/jco.18.00204.
• Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 5347-5356. PMID: 29898988, PMCID: PMC6324578, DOI: 10.1158/1078-0432.CCR-18-1116.
• Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint InhibitorsStamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: dbi180002. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.
• Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805Jilaveanu LB, Puligandla M, Weiss SA, Wang X, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research 2018, 24: 217-223. PMID: 29066509, PMCID: PMC5904512, DOI: 10.1158/1078-0432.ccr-17-1555.
• Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the LiteratureUtter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology 2017, 93: 249-258. PMID: 28746931, PMCID: PMC5617794, DOI: 10.1159/000478050.
• Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy.Lattanzi M, Lee Y, Robinson E, Weiss S, Moran U, Simpson D, Shapiro R, Berman R, Pavlick A, Wilson M, Kirchhoff T, Zhong J, Osman I. Primary melanoma histologic subtype (HS) impacts melanoma specific survival (MSS) and response to systemic therapy. Journal Of Clinical Oncology 2017, 35: 9577-9577. DOI: 10.1200/jco.2017.35.15_suppl.9577.
• Targeting EZH2 in acral lentiginous melanoma (ALM).Izsak A, Giles K, Lui K, Weiss S, Moran U, Vega-Saenz de Miera E, Stein J, Lee A, Darvishian F, Shapiro R, Berman R, Pavlick A, Wilson M, Osman I. Targeting EZH2 in acral lentiginous melanoma (ALM). Journal Of Clinical Oncology 2017, 35: 9534-9534. DOI: 10.1200/jco.2017.35.15_suppl.9534.
• Microvessel density as a prognostic marker in high-risk renal cell carcinoma.Weiss S, Puligandla M, Jilaveanu L, Haas N, Wang X, Zito C, Boeke M, Neumeister V, Manola J, DiPaola R, Kluger H. Microvessel density as a prognostic marker in high-risk renal cell carcinoma. Journal Of Clinical Oncology 2017, 35: 4565-4565. DOI: 10.1200/jco.2017.35.15_suppl.4565.
• Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25)Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25). Human Pathology 2017, 63: 222. PMID: 28449825, DOI: 10.1016/j.humpath.2017.03.001.
• From the Guest EditorsWeiss SA, Kluger HM. From the Guest Editors. The Cancer Journal 2017, 23: 1-2. PMID: 28114248, PMCID: PMC5526070, DOI: 10.1097/ppo.0000000000000244.
• Melanoma brain metastases: correlation of imaging features with genomic markers and patient survivalBordia R, Zhong H, Lee J, Weiss S, Han SW, Osman I, Jain R. Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival. Journal Of Neuro-Oncology 2016, 131: 341-348. PMID: 27822597, DOI: 10.1007/s11060-016-2305-8.
• Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohortsWeiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. Journal Of Translational Medicine 2016, 14: 299. PMID: 27760559, PMCID: PMC5070187, DOI: 10.1186/s12967-016-1026-2.
• Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanomaWeiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Human Pathology 2016, 57: 116-125. PMID: 27473267, PMCID: PMC5706446, DOI: 10.1016/j.humpath.2016.07.008.
• Impact of aging on immune response and survival in melanoma.Weiss S, Tchack J, Han J, Darvishian F, Shapiro R, Krogsgaard M, Zhong J, Osman I. Impact of aging on immune response and survival in melanoma. Journal Of Clinical Oncology 2016, 34: e21079-e21079. DOI: 10.1200/jco.2016.34.15_suppl.e21079.
• Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.Weiss S, Martinez C, Vega-Saenz de Miera E, Dolgalev I, Shapiro R, Heguy A, Hernando E, Kirchhoff T, Osman I. Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target. Journal Of Clinical Oncology 2016, 34: 9524-9524. DOI: 10.1200/jco.2016.34.15_suppl.9524.
• Chapter 20 Management of Melanoma Therapy-Associated ToxicitiesWeiss S, Kavecansky J, Pavlick A. Chapter 20 Management of Melanoma Therapy-Associated Toxicities. 2016, 299-319. DOI: 10.1016/b978-0-12-803508-5.00020-2.
• Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasisWeiss S, Darvishian F, Tadepalli J, Shapiro R, Golfinos J, Pavlick A, Polsky D, Kirchhoff T, Osman I. Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis. BMC Cancer 2015, 15: 926. PMID: 26597176, PMCID: PMC4657192, DOI: 10.1186/s12885-015-1927-0.
• Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progressionChang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D. Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression. Molecular Oncology 2015, 10: 157-165. PMID: 26440707, PMCID: PMC4695284, DOI: 10.1016/j.molonc.2015.09.005.
• Revisiting determinants of prognosis in cutaneous melanomaWeiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. Cancer 2015, 121: 4108-4123. PMID: 26308244, PMCID: PMC4666819, DOI: 10.1002/cncr.29634.
• Dabrafenib for the treatment of melanomaWeiss S, Pavlick A. Dabrafenib for the treatment of melanoma. Expert Opinion On Orphan Drugs 2015, 3: 1075-1084. DOI: 10.1517/21678707.2015.1067136.
• Role of the Medical Oncologist in the Management of Skin CancerWeiss S, Wilson M, Pavlick A. Role of the Medical Oncologist in the Management of Skin Cancer. Current Dermatology Reports 2015, 4: 205-212. DOI: 10.1007/s13671-015-0119-0.
• The impact of primary melanoma histotype on overall survival and response to immunotherapy.Robinson E, Salvaggio C, Han S, Weiss S, Wilson M, Silva I, Berman R, Polsky D, Shapiro R, Pavlick A, Zhong J, Osman I. The impact of primary melanoma histotype on overall survival and response to immunotherapy. Journal Of Clinical Oncology 2015, 33: e20078-e20078. DOI: 10.1200/jco.2015.33.15_suppl.e20078.
• Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas.Weiss S, Han S, Vogelsang M, Krogsgaard M, Lui K, Shapiro R, Kirchhoff T, Darvishian F, Osman I. Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas. Journal Of Clinical Oncology 2015, 33: e20042-e20042. DOI: 10.1200/jco.2015.33.15_suppl.e20042.
• Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival.Lui K, Silva I, Weiss S, Han S, Darvishian F, Pavlick A, Golfinos J, Moogk D, Krogsgaard M, Osman I. Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival. Journal Of Clinical Oncology 2015, 33: 9070-9070. DOI: 10.1200/jco.2015.33.15_suppl.9070.
• Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanomaWengrod J, Wang D, Weiss S, Zhong H, Osman I, Gardner LB. Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma. Science Signaling 2015, 8: ra27. PMID: 25759478, PMCID: PMC4580977, DOI: 10.1126/scisignal.aaa0899.
• Update on Vaccines for High-Risk MelanomaWeiss SA, Chandra S, Pavlick AC. Update on Vaccines for High-Risk Melanoma. Current Treatment Options In Oncology 2014, 15: 269-280. PMID: 24788575, DOI: 10.1007/s11864-014-0283-7.